IL17A and psoriasis: The intra-articular injection of DT selectively depletes synovial TRM cells, resulting in attenuated joint flares in RA.393 In addition, IL-17A produced by CD8+TRM cells contributes to local inflammatory injury, and patients with PsA, autoimmune kidney disease, and psoriasis may benefit from IL-17-blockade therapy.19,106,411,412